Core Insights - MetaVia Inc. has announced an expansion of its global patent protection for vanoglipel, a novel GPR119 agonist, with a portfolio of 48 granted and pending patents across multiple regions, providing protection until 2035 unless extended [1] - The patents cover the core compound, manufacturing processes, and potential therapeutic uses for serious metabolic and liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes (T2D) [1] - The CEO emphasized the importance of a strong intellectual property position to maximize the long-term value of vanoglipel, highlighting its broad therapeutic potential [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing vanoglipel (DA-1241) for MASH and DA-1726 for obesity [1] - Vanoglipel promotes the release of gut peptides that are beneficial for glucose and lipid metabolism, showing positive effects in preclinical studies and early-phase clinical trials [1] - DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, demonstrating best-in-class potential for weight loss and glucose control in clinical trials [1] Clinical Development - Vanoglipel has shown efficacy in reducing hepatic steatosis, inflammation, and fibrosis while improving glucose control in preclinical models of MASH and T2D [1] - In Phase 1a, 1b, and 2a trials, vanoglipel was well tolerated among participants, including healthy volunteers and those with T2D [1] - A Phase 2a clinical study indicated that vanoglipel has direct hepatic action alongside its glucose-lowering effects [1]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 18, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEUROBO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 47-2389984 (IRS Employer Identification Number ...